- 1 Title: Effect of Antibiotic and Steroid Treatment on Leptospirosis Outcomes: A Single-Center
- 2 Retrospective Cohort Study in the Transcarpathian Region of Ukraine
- 3 Author names and affiliations.
- 4 Pavlo Petakh^{1,2*}, Valentyn Oksenych^{3*}, Mykhailo Poliak^{4,5}, Ivan Poliak⁵, Anton Kohutych⁵,
- 5 Oleksandr Kamyshnyi²
- ¹Department of Biochemistry and Pharmacology, Uzhhorod National University, Uzhhorod, Ukraine;
- ⁷ Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National
- 8 Medical University, Ternopil, Ukraine;
- 9 ³Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen,
- 10 5020 Bergen, Norway;
- ⁴Department of Pediatrics with Pediatric Infectious Diseases, Uzhhorod National University, 88000
- 12 Uzhhorod, Ukraine;

- ⁵Transcarpathian Regional Clinical Infectious Hospital, Uzhhorod, Ukraine;
- 14 Corresponding author: Department of Biochemistry and Pharmacology, Uzhhorod National
- University, Uzhhorod, Ukraine; pavlo.petakh@uzhnu.edu.ua (P.P.)
- Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, 5020
- Bergen, Norway; valentyn.oksenych@uib.no (V.O.)

Abstract

Leptospirosis presents a significant health challenge in the Transcarpathian region of Ukraine, with higher incidence rates and mortality compared to national averages. We conducted a retrospective cohort study to investigate the effects of antibiotic and steroid treatments on outcomes in leptospirosis patients. Our analysis of clinical and laboratory data from a single center revealed that dexamethasone showed significant effects on various clinical variables, as did investigated antibiotics. Particularly, direct bilirubin levels emerged as a strong predictor of death. These findings provide valuable insights for clinicians in managing leptospirosis, aiding in outcome prediction and treatment decision-making not only in the Transcarpathian region but globally.

Keywords: leptospirosis; corticosteroids; outcome; antibiotic; dexamethasone; predictors

1. Introduction

- 32 Leptospirosis, a disease primarily found in tropical regions, is a zoonotic illness transmitted through
- contact with the urine of animals, particularly rats [1]. Its clinical manifestations range from mild to
- 34 severe, posing life-threatening consequences. Symptoms often mimic those of other infectious
- diseases, such as influenza [2]. Severe cases, affecting approximately 5% to 15% of individuals,
- manifest with acute renal failure, acute respiratory distress syndrome, pulmonary issues, hypotension,
- icterus, and altered mental status [3-7].
- In the Transcarpathian region, leptospirosis persists as a prevalent zoonotic disease. Between 2005
- and 2015, 420 cases were reported, with an incidence three times higher than the national average.
- 40 The case fatality rate (CFR) for leptospirosis in Transcarpathia averages 12.5%, exceeding the
- 41 national level of 9.8% [8-10].
- 42 Analysis reveals a significant increase in the notification rate of leptospirosis in Ukraine in 2023. This
- surge is primarily attributed to the rising incidence of leptospirosis in Transcarpathia, accounting for
- 150 cases out of the total 433 in Ukraine, and the Ivano-Frankivsk region, contributing 34 cases [11]
- 45 (Figure 1).
- Pathogenic Leptospira, responsible for the disease, are excreted in the urine of rats, with humans
- 47 inadvertently becoming hosts and facing potentially life-threatening consequences [7]. Rats,
- 48 however, remain immune to fatal infection, serving as natural reservoirs. Most human leptospiral
- 49 infections are either mild or asymptomatic. Those who do develop the illness typically experience an
- abrupt onset of symptoms, including fever, rigors, myalgias, and headache [6, 9].
- The disease unfolds in two phases [12]. The initial phase involves an acute febrile bacteraemia lasting
- 2 to 9 days, followed by a period of reduced or no fever and apparent improvement. The second
- 53 phase, known as the "immune" phase, is characterised by renewed fever and the emergence of
- complications. Approximately 5%–15% of patients may progress to Weil's disease, with pulmonary
- involvement being a notable feature (20%–70%) [7]. Pulmonary complications range from mild
- cough to severe symptoms like haemoptysis and Acute respiratory distress syndrome (ARDS), the
- latter carrying a high mortality rate of around 50% [13-15].
- The role of corticosteroids in treating severe leptospirosis, especially in addressing pulmonary
- 59 complications like ARDS, has been explored in a limited number of studies. The argument posits that
- 60 multi-organ failure in leptospirosis may result from an overactive immune system rather than the
- direct effects of the pathogen [16]. Therefore, the use of therapeutic doses of steroids is considered
- to counteract immune activation, potentially reducing mortality and morbidity in severe leptospirosis
- cases [17]. However, the efficacy of corticosteroids remains uncertain due to the scarcity of studies.

- This study aims to investigate the effects of antibiotic and steroid treatment on outcomes in patients
- diagnosed with leptospirosis within the Transcarpathian Region of Ukraine. Through a retrospective
- analysis of clinical and laboratory data from a single-center cohort, we aim to assess the impact of
- 67 these treatments on patient morbidity and mortality rates. Additionally, we aim to explore potential
- associations between treatment regimens and clinical outcomes, thereby providing significant
- 69 contributions to the understanding and management of leptospirosis in this geographical area.

2. Material and Methods

- 71 2.1. Study design and diagnostic criteria
- We conducted a retrospective single-center cohort study. All medical records were obtained from the
- 73 Transcarpathian Regional Clinical Infectious Diseases Hospital, Ukraine. Confirmation of diagnosis
- was determined by the order of the Ministry of Health of Ukraine No. 905 of December 28, 2015.
- 75 This includes fever or at least two of the following symptoms: chills, headache, myalgia, conjunctival
- hyperemia, skin and mucous membrane hemorrhages, rash, jaundice, myocarditis, meningitis, kidney
- failure, respiratory manifestations such as hemoptysis, and laboratory confirmation by Polymerase
- 78 Chain Reaction (PCR) or MAT (Microscopic Agglutination Test).
- 79 Inclusion Criteria: Patients included in this study met the following criteria: diagnosed with
- leptospirosis according to the criteria outlined by the Ministry of Health of Ukraine; with medical
- 81 records available at the Transcarpathian Regional Clinical Infectious Diseases Hospital; confirmed
- laboratory diagnosis by PCR or MAT; complete clinical and laboratory data for analysis; aged 18
- years and older; and non-pregnant.
- 84 Exclusion Criteria: Patients were excluded from the study if they met any of the following criteria:
- 85 incomplete medical records or missing key diagnostic information; incomplete or inconsistent
- laboratory confirmation results; history of receiving medications that could interfere with the study
- variables or outcomes; younger than 18 years old; or pregnant.
- 88 2.2. Patient Stratification and Grouping
- We have grouped these patients into different groups for comparing clinical and laboratory data.
- 90 Firstly, based on sex, males (n=27) and females (n=11). Secondly, based on steroid treatments, the
- majority received dexamethasone 8 mg per day (n=29), while a few received methylprednisolone 250
- mg per day (n=2), and others included patients prescribed prednisolone 1 mg/kg/day or combination
- 93 steroid types (n=4), with 3 patients not receiving steroids. Next, we grouped the patients based on
- antibiotic treatment into large groups, i.e. those treated with cephalosporins (n=17), benzylpenicillins
- 95 (n=8), and others treated with carbapenems or macrolides (n=13). Finally, the patients were also
- grouped based on outcomes, i.e. 35 survivors and 3 non-survivors.

2.3 Statistical analysis

98 Power analysis was conducted to ascertain the appropriate sample size necessary to detect statistically

significant effects or differences in our study variables, while maintaining a desired level of statistical

100 power.

97

99

- Quantitative variables following a non-normal distribution were described using the median (Me) and
- lower and upper quartiles (Q1 Q3). Categorical data were described using absolute and relative
- frequencies. Comparisons of three or more groups on a quantitative variable with a distribution
- differing from normality were made using the Kruskal-Wallis test, with Dunn's criterion and Holm
- correction applied as a *post hoc* method. The Wilcoxon test was employed for comparing quantitative
- variables following a non-normal distribution between two matched samples. The Mann-Whitney U-
- test was used to compare two groups on a quantitative variable with a distribution differing from
- 108 normality. Frequencies in the analysis of multifield contingency tables were compared using
- 109 Pearson's chi-square test.
- 110 ROC analysis was utilized to assess the diagnostic performance of quantitative variables in predicting
- a categorical outcome. The optimal cut-off value of the quantitative variable was estimated using
- 112 Youden's J statistic.
- Statistical significance was determined at p < 0.05.
 - 3. Results

- 3.1. Descriptive analysis and sex-dependent changes in variables
- Overall, 38 patients were included in our study, of whom 35 survived and 3 died (7.89%). The socio-
- demographic and clinical presentations, and laboratory findings of all confirmed patients are shown
- in Table 1.
- The 38 patients comprised 27 (71.1%) males and 11 (28.9%) females, with a median age of
- 50.00 years (Table 2). Additionally, we conducted a sex-dependent investigation of clinical and
- laboratory variables on admission. We found significant changes in Mean Corpuscular Volume
- 122 (MCV) (p = 0.002), with males having 91.00 (88.50 94.30) fL and females having 87.00 (83.50 -
- 88.50) fL. Males had statistically higher Alanine Aminotransferase (ALT) levels (p = 0.0048) than
- 124 females, with values of 93.30 (65.20 134.15) U/L compared to 61.50 (38.75 100.55) U/L,
- respectively. Similarly, males had higher Aspartate Aminotransferase (AST) levels (p = 0.020) at
- 81.30 (54.90 148.95) U/L compared to females at 47.00 (30.55 73.55) U/L.
- 3.2. Effect of steroid type on clinical and laboratory findings

Most patients took dexamethasone, comprising 29 out of 38 patients (76.3%). Additionally, only 2 patients (5.3%) received methylprednisolone. Four patients were administered other types of steroids, while three patients did not receive any steroid treatment during their hospitalization.

When we compared laboratory findings before admission and after discharge, we found statistically significant changes only in the group that took dexamethasone. The statistically significant changes were observed in Lymphocytes (LYM) levels (on admission: 0.79 ×10⁹/L (0.44 -1.45), on discharge: 2.30×10^9 /L (1.59 -2.99), p < 0.001), Mid-sized Cells (MID) (on admission: $0.30 \times 10^{9}/L$ (0.14 – 0.47), on discharge: $0.71 \times 10^{9}/L$ (0.56 – 0.81), p = 0.002), Granulocytes (GRA) levels (on admission: 8.18×10^9 /L (6.25 – 12.16), on discharge: 6.28×10^9 /L (5.00 – 7.87), p = 0.033), Red Blood Cells (RBC) (on admission: $4.64 \times 10^{12}/L$ (4.17 - 4.91), on discharge: $4.30 \times 10^{12}/L$ (3.63-4.66), p = 0.004), MCV (on admission: 90.00 fL (87.00 – 92.00), on discharge: 93.00 fL (89.00 – 95.00), p = 0.004), Platelets (PLT) levels (on admission: 123.00×10^9 /L (68.00 – 182.00), on discharge: $320.00 \times 10^{9}/L$ (204.00 – 350.00), p < 0.001), AST (on admission: 72.30 U/L (37.30 – 122.00), on discharge: 41.50 U/L (30.50 - 58.10), p = 0.016), Direct bilirubin (on admission: 14.40 μ mol/L (5.68 – 68.70), on discharge: 10.50 μ mol/L (5.70 – 21.20), p = 0.026), and Urea levels (on admission: 9.63 mmol/L (8.22 – 23.02), on discharge: 7.80 mmol/L (6.65 – 8.63), p = 0.005). All other laboratory parameters such as White Blood Cells (WBC) (×10⁹/L), Erythrocyte Sedimentation Rate (ESR) (mm/hr), Hemoglobin (HGB) (g/L), ALT (U/L), Serum Creatinine (µmol/L), glucose (mmol/L), Gamma-Glutamyl Transferase (GGT) (U/L), Total Bilirubin (µmol/L), Total Protein (g/L) did not show significant differences between admission and discharge (p > 0.05) (Figure 2).

3.3. Effect of antibiotic treatment on clinical and laboratory findings

We divided patients into 3 groups, i.e. those who were prescribed cephalosporins - 17 patients, those who were prescribed benzylpenicillin - 8 patients, and a group receiving alternative antimicrobial therapy - 13 patients. We compared the differences in the same indicators as when comparing the effects of steroids.

When comparing laboratory findings before admission and after discharge, we observed statistically significant changes in the LYM (p=0.002), MID (p=0.027), MCV (p=0.006), PLT (p=0.003), AST (p=0.015), glucose (p=0.045), Total Bilirubin (p=0.009), Direct bilirubin (p=0.015), and Urea (p=0.013) for the group treated with cephalosporins. Patients treated with benzylpenicillins exhibited statistically significant changes in LYM (p=0.039), MID (p=0.028), RBC (p=0.039), HGB (p=0.028), and PLT (p=0.039). Patients receiving alternative antimicrobial therapy experienced significant changes in LYM (p=0.033), RBC (p=0.008), MCV (p=0.033), PLT (p=< 0.001), Serum Creatinine (p=<0.001), Direct bilirubin (p=0.048), and Urea (p=0.010) (Table 3). When we compared the effect of antibiotics and steroids on the length of stay (LoS) and outcomes, we did not find any significant differences across the groups (Figure 3).

3.4. Effect of laboratory variables on outcome

The non-survivor group had statistically higher serum creatinine levels on admission compared to the survivor group (137.30 [111.80 – 321.90] vs. 541.30 [506.10 – 570.60], p = 0.032) and GGT levels (75.60 [49.85 – 125.55] vs. 185.30 [163.75 – 442.35], p = 0.032). Total bilirubin levels were significantly higher in the non-survivor group compared to the survivor group (491.60 [343.95 – 563.30] vs. 25.90 [11.35 – 82.76], p = 0.010), as were direct bilirubin levels (257.10 [199.30 – 398.85] vs. 14.40 [5.84 – 53.80], p = 0.010). Additionally, urea levels were higher in the non-survivor group (30.80 [30.59 – 38.15] vs. 9.63 [8.20 – 21.25], p = 0.019).

Moreover, we conducted Receiver Operating Characteristic (ROC) analysis. We found that all variables had 100% sensitivity as potential predictors of death, except for GGT, which had a sensitivity of 66.8%. The specificity was lowest for GGT (77.1%), followed by serum creatinine (85.7%), total bilirubin and urea (both 88.6%), and the highest specificity was for direct bilirubin (91.4%) (Figure 4).

4. Discussion

The Transcarpathian region experienced a significantly higher notification rate in 2023, with 150 out of 433 reported cases originating from this area. Situated in the western part of Ukraine, the region shares borders with Romania, Hungary, Poland, and Slovakia [8]. It sustains an above-average human population density, with 63% residing in rural regions, which may impact notification rates [18].

We observed that males had higher levels of transaminases such as AST, ALT, and GGT, but this did not affect outcomes. Our findings align with a study conducted in Germany, which revealed that male patients were more likely than female patients to be hospitalized and exhibit symptoms of severe leptospirosis, including jaundice, renal impairment, and haemorrhage [19].

Only four studies were found that investigated the role of steroids in clinical outcomes in leptospirosis. In three of these studies, methylprednisolone was administered at the initiation of treatment, albeit at varying doses. They suggested a potential beneficial role of steroids, particularly in patients with lung involvement [20-22]. However, the study that employed dexamethasone at the initiation failed to show a treatment benefit and, notably, reported an elevated incidence of nosocomial infections [23].

In regards to the effect of antibiotics on leptospirosis, we found a newly conducted meta-analysis involving 920 patients and 8 antibiotics. The analysis revealed that six antibiotics resulted in significantly shorter defervescence times compared to the control group. These antibiotics include cefotaxime, azithromycin, doxycycline, ceftriaxone, penicillin, and penicillin or ampicillin. However, antibiotics were not found to be effective in reducing mortality or hospital stays [24].

Lastly, concerning factors influencing leptospiral outcomes, we conducted our own metaanalysis of clinical predictors involving 1714 patients with leptospirosis. We found that patients with severe outcomes were more likely to experience dyspnea, oliguria, and hemorrhagic symptoms compared to non-severe patients [9].

5. Conclusions

197

198

199

200

201

208

- We observed that dexamethasone had a statistically significant effect on certain clinical variables,
- such as LYM, MID, GRA, Platelet levels, AST, direct bilirubin, and urea levels. Similarly,
- 204 cephalosporins showed significant effects on LYM, MID, Platelet, AST, total bilirubin, direct
- bilirubin, and urea levels. Notably, direct bilirubin levels emerged as one of the strongest predictors
- of death in leptospirosis, exhibiting high sensitivity and specificity. These findings have implications
- for clinicians not only in the Transcarpathian region but also for practitioners worldwide.

6. Conflict of Interest

- The authors declare that the research was conducted in the absence of any commercial or financial
- 210 relationships that could be construed as a potential conflict of interest.

7. Funding

- 212 This research received no specific grant from any funding agency in the public, commercial, or not-
- 213 for-profit sectors.

214 8. Author Contributions

- 215 Conceptualization, and writing—original draft preparation, P.P.; writing—review and editing, M.P.,
- A.K., V.O., I.P.; supervision, O.K.; visualization, O.K., P.P.; All authors have read and agreed to the
- 217 published version of the manuscript.

9. Institutional Review Board Statement

- The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics
- 220 Committee of Uzhhorod National University (protocol code 5/1 on 30 May 2024).

221 10. Data Availability Statement

The data presented in this study are available on request from the corresponding author.

223 11. References

- Haake DA, Levett PN. Leptospirosis in humans. J Leptospira leptospirosis. 2015:65-97.
- 225 [2] Philip N, Lung Than LT, Shah AM, Yuhana MY, Sekawi Z, Neela VK. Predictors of severe
- leptospirosis: a multicentre observational study from Central Malaysia. J BMC Infectious Diseases.
- 227 2021;21(1):1-6.

- 228 [3] Spichler AS, Vilaça PJ, Athanazio DA, Albuquerque JO, Buzzar M, Castro B, et al. Predictors
- of lethality in severe leptospirosis in urban Brazil. The American journal of tropical medicine and
- 230 hygiene. 2008;79(6):911.
- 231 [4] Panaphut T, Domrongkitchaiporn S, Thinkamrop B. Prognostic factors of death in
- leptospirosis: a prospective cohort study in Khon Kaen, Thailand. International Journal of Infectious
- 233 Diseases. 2002;6(1):52-9.
- Doudier B, Garcia S, Quennee V, Jarno P, Brouqui PJCM, Infection. Prognostic factors
- associated with severe leptospirosis. Wiley Online Library; 2006. p. 299-300.
- Petakh P, Isevych V, Mohammed IB, Nykyforuk A, Rostoka L. Leptospirosis: Prognostic
- 237 Model for Patient Mortality in the Transcarpathian Region, Ukraine. Vector borne and zoonotic
- 238 diseases (Larchmont, NY). 2022;22(12):584-8.
- 239 [7] Petakh P, Isevych V, Kamyshnyi A, Oksenych V. Weil's Disease-Immunopathogenesis,
- Multiple Organ Failure, and Potential Role of Gut Microbiota. Biomolecules. 2022;12(12).
- 241 [8] Markovych O, Tymchyk V, Kolesnikova I. Leptospirosis in Zakarpattia Oblast (2005–2015).
- Vector-Borne and Zoonotic Diseases. 2019;19(5):333-40.
- 243 [9] Petakh P, Rostoka L, Isevych V, Kamyshnyi A. Identifying risk factors and disease severity
- in leptospirosis: A meta-analysis of clinical predictors. Tropical doctor. 2023;53(4):464-9.
- 245 [10] Petakh P, Kamyshnyi A, Tymchyk V, Armitage R. Infectious diseases during the Russian-
- Ukrainian war Morbidity in the Transcarpathian region as a marker of epidemic danger on the EU
- border. Public Health in Practice. 2023;6:100397.
- 248 [11] Pavlo P, Viktoriia T, Oleksandr K. Surveillance of human leptospirosis infections in Ukraine
- 249 between 2018 and 2023 Front Public Health. 2024;12.
- 250 [12] Xavier V, Baby B, George JM, Ittyachen AM. Covid-19 and leptospirosis, pulmonary
- involvement and response to steroids: A comparative observational study from a rural Tertiary care
- center in Kerala. Journal of family medicine and primary care. 2022;11(1):294-8.
- 253 [13] Gulati S, Gulati A. Pulmonary manifestations of leptospirosis. Lung India: official organ of
- 254 Indian Chest Society. 2012;29(4):347-53.
- Dolhnikoff M, Mauad T, Bethlem EP, Carvalho CRR. Pathology and pathophysiology of
- 256 pulmonary manifestations in leptospirosis. J Brazilian Journal of Infectious Diseases.
- 257 2007;11(1):142-8.
- Vieira SR, Brauner JS. Leptospirosis as a cause of acute respiratory failure: clinical features
- and outcome in 35 critical care patients. The Brazilian journal of infectious diseases: an official
- publication of the Brazilian Society of Infectious Diseases. 2002;6(3):135-9.
- 261 [16] Limothai U, Lumlertgul N, Sirivongrangson P, Kulvichit W, Tachaboon S, Dinhuzen J, et al.
- The role of leptospiremia and specific immune response in severe leptospirosis. J Scientific reports.
- 263 2021;11(1):1-9.

- 264 [17] Petakh P, Nykyforuk A. Predictors of lethality in severe leptospirosis in Transcarpathian
- region of Ukraine. Le infezioni in medicina. 2022;30(2):272-6.
- 266 [18] Wasiński B, Dutkiewicz J. Leptospirosis-current risk factors connected with human activity
- and the environment. Annals of agricultural and environmental medicine: AAEM. 2013;20(2):239-
- 268 44.
- 269 [19] Jansen A, Stark K, Schneider T, Schöneberg I. Sex differences in clinical leptospirosis in
- Germany: 1997-2005. Clinical infectious diseases : an official publication of the Infectious Diseases
- 271 Society of America. 2007;44(9):e69-72.
- 272 [20] Ittyachen M A, Vk L, Ck E, Joseph M. Methylprednisolone as adjuvant in treatment of acute
- 273 respiratory distress syndrome owing to leptospirosis A pilot study. Indian Journal of Critical Care
- 274 Medicine (ISSN: 0972-5229) Vol 9 Num 3. 2005;9.
- 275 [21] Kularatne SA, Budagoda BD, de Alwis VK, Wickramasinghe WM, Bandara JM, Pathirage
- LP, et al. High efficacy of bolus methylprednisolone in severe leptospirosis: a descriptive study in Sri
- 277 Lanka. Postgraduate medical journal. 2011;87(1023):13-7.
- 278 [22] Shenoy VV, Nagar VS, Chowdhury AA, Bhalgat PS, Juvale NI. Pulmonary leptospirosis: an
- excellent response to bolus methylprednisolone. Postgraduate medical journal. 2006;82(971):602-6.
- Niwattayakul K, Kaewtasi S, Chueasuwanchai S, Hoontrakul S, Chareonwat S, Suttinont C,
- et al. An open randomized controlled trial of desmopressin and pulse dexamethasone as adjunct
- therapy in patients with pulmonary involvement associated with severe leptospirosis. Clinical
- 283 microbiology and infection: the official publication of the European Society of Clinical Microbiology
- and Infectious Diseases. 2010;16(8):1207-12.
- Ji Z, Jian M, Su X, Pan Y, Duan Y, Ma W, et al. Efficacy and safety of antibiotics for treatment
- of leptospirosis: a systematic review and network meta-analysis. Systematic reviews. 2024;13(1):108.

Table 1. Demographic and Clinical Characteristics of Patients with Leptospirosis in the Transcarpathian Region of Ukraine

| | Abs. | % | | | | |
|----------------------|----------|------|--|--|--|--|
| Sex | | | | | | |
| Male | 27 | 71.1 | | | | |
| Female | 11 | 28.9 | | | | |
| Serogroups | | | | | | |
| Hebdomadis | 10 | 26.3 | | | | |
| Canicola | 4 | 10.5 | | | | |
| Clinical | 3 | 7.9 | | | | |
| Others | 2 | 5.3 | | | | |
| Pomona | 3 | 7.9 | | | | |
| Sejroe | 5 | 13.2 | | | | |
| Icterrohaemorrhagiae | 3 | 7.9 | | | | |
| Cynopteri | 7 | 18.4 | | | | |
| Australis | 1 | 2.6 | | | | |
| Outcome | | | | | | |
| Survive | 35 | 92.1 | | | | |
| Non-survive | 3 | 7.9 | | | | |
| Antibiotic | | | | | | |
| Cephalosporins | 17 | 44.7 | | | | |
| Benzylpenicillins | 8 | 21.1 | | | | |
| Others | 13 | 34.2 | | | | |
| | Steroids | | | | | |
| None | 3 | 7.9 | | | | |
| Dexamethasone | 29 | 76.3 | | | | |
| Methylprednisolone | 2 | 5.3 | | | | |
| Others | 4 | 10.5 | | | | |

Table 2. Clinical and Laboratory Findings at Admission for Patients with Leptospirosis

| Variables | Median (Me) | Q ₁ – Q ₃ (Interquartile Range) |
|-----------------------------|-------------|---|
| Age (years) | 50.00 | 44.25 – 63.75 |
| Length of Stay (LoS) (days) | 10.00 | 7.00 – 11.75 |
| WBC (×10°/L) | 10.73 | 6.87 - 14.81 |
| LYM (×10°/L) | 0.71 | 0.43 - 1.45 |
| MID (×109/L) | 0.31 | 0.14 - 0.63 |
| GRA (×10°/L) | 8.18 | 6.25 – 13.38 |
| ESR (mm/hr) | 46.50 | 30.00 - 75.25 |
| RBC (×1012/L) | 4.38 | 4.08 - 4.91 |
| HGB (g/L) | 128.00 | 113.50 – 140.75 |
| MCV (fL) | 89.50 | 87.00 - 92.00 |
| PLT (×10°/L) | 116.50 | 68.00 – 181.25 |
| ALT (U/L) | 92.15 | 55.00 – 128.85 |
| AST (U/L) | 76.15 | 44.52 – 123.35 |
| Serum Creatinine (µmol/L) | 138.90 | 112.67 – 421.27 |
| Glucose (mmol/L) | 7.28 | 6.55 - 9.04 |
| GGT (U/L) | 85.75 | 52.62 - 157.88 |
| Total Bilirubin (µmol/L) | 34.00 | 12.47 – 121.80 |
| Direct Bilirubin (µmol/L) | 19.35 | 6.22 – 91.58 |
| Total Protein (g/L) | 61.20 | 55.25 – 63.27 |
| Urea (mmol/L) | 10.82 | 8.26 - 23.08 |

Table 3. Effect of Antibiotics on Laboratory Findings

| Variables | Group | On Admission (Median [Q1 – Q3]) | On Discharge (Median [Q1 – Q3]) | P value |
|----------------------------|-------------------|---------------------------------------|---------------------------------------|----------|
| WBC (×10°/L) | Cephalosporins | 8.39 (6.59 – 14.01) | 9.25 (7.86 – 12.86) | 0.747 |
| | Benzylpenicillins | 9.87 (7.49 – 12.73) | 8.96 (6.77 – 11.04) | 0.844 |
| | Others | 11.68 (7.12 – 18.00) | 9.62 (7.31 – 12.08) | 0.414 |
| $LYM (\times 10^9/L)$ | Cephalosporins | 0.62(0.39 - 1.20) | 2.50 (1.68 – 3.02) | 0.002* |
| | Benzylpenicillins | 0.60 (0.43 - 0.86) | 1.73 (1.25 – 1.91) | 0.039* |
| | Others | 1.18 (0.53 - 2.14) | 2.05(1.58 - 2.81) | 0.033* |
| $MID (\times 10^{9}/L)$ | Cephalosporins | 0.24 (0.14 - 0.39) | 0.68 (0.43 - 0.81) | 0.027* |
| | Benzylpenicillins | 0.34 (0.29 - 0.51) | 0.84 (0.54 - 1.09) | 0.028* |
| | Others | 0.36 (0.13 - 0.99) | 0.71 (0.62 - 0.75) | 0.497 |
| GRA (×10°/L) | Cephalosporins | 7.39 (6.15 – 12.16) | 6.73 (5.08 – 8.71) | 0.109 |
| | Benzylpenicillins | 8.46 (6.70 – 11.77) | 6.03 (5.00 – 7.95) | 0.250 |
| | Others | 8.54 (6.25 – 15.20) | 6.94 (4.70 – 7.87) | 0.094 |
| ESR (mm/hr) | Cephalosporins | 40.00 (27.00 – 63.00) | 33.00 (20.00 – 60.00) | 0.378 |
| | Benzylpenicillins | 63.50 (31.50 – 79.25) | 51.50 (34.50 – 75.25) | 0.641 |
| | Others | 59.00 (41.00 – 82.00) | 49.00 (41.00 – 70.00) | 0.127 |
| RBC (×10 ¹² /L) | Cephalosporins | 4.48 (4.24 – 5.01) | 4.33 (3.89 – 4.93) | 0.207 |
| | Benzylpenicillins | 4.01 (3.80 – 4.80) | 3.67 (3.56 – 4.07) | 0.039* |
| | Others | 4.38 (4.16 – 4.80) | 4.37 (3.46 – 4.50) | 0.008* |
| HGB (g/L) | Cephalosporins | 130.00 (123.00 – 140.00) | 125.00 (116.00 – 144.00) | 0.782 |
| | Benzylpenicillins | 121.50 (112.75 – 127.25) | 115.50 (112.00 – 117.75) | 0.028* |
| | Others | 127.00 (110.00 – 142.00) | 127.00 (102.00 – 138.00) | 0.340 |
| MCV (fL) | Cephalosporins | 90.00 (87.00 – 92.00) | 92.00 (89.00 – 94.00) | 0.006* |
| | Benzylpenicillins | 90.00 (86.75 – 93.00) | 91.50 (88.50 – 95.25) | 0.250 |
| | Others | 89.00 (87.00 – 95.00) | 90.00 (88.00 – 97.00) | 0.033* |
| PLT (×10°/L) | Cephalosporins | 136.00 (73.00 – 229.00) | 346.00 (293.00 – 398.00) | 0.003* |
| | Benzylpenicillins | 85.00 (49.75 – 150.50) | 174.50 (132.25 – 338.50) | 0.039* |
| | Others | 107.00 (68.00 – 139.00) | 278.00 (228.00 – 339.00) | < 0.001* |
| ALT (U/L) | Cephalosporins | 93.00 (41.60 – 169.30) | 85.40 (64.40 – 106.80) | 0.159 |
| | Benzylpenicillins | 85.65 (68.72 – 247.22) | 68.50 (62.27 – 132.75) | 0.250 |

| | | 85.30 | 55.90 | |
|---------------------------------|-------------------|-----------------------------|-----------------------------|----------|
| | Others | (53.80 – 120.60) | (41.10 – 98.50) | 0.839 |
| AST (U/L) | Cephalosporins | 81.30 (39.10 – 135.80) | 49.30 (34.50 – 58.10) | 0.015* |
| | Benzylpenicillins | 69.80 (48.12 – 156.90) | 49.15 (27.60 – 93.25) | 0.109 |
| | Others | 76.20 (44.10 – 103.00) | 37.50 (27.60 – 53.90) | 0.168 |
| Serum Creatinine (µmol/L) | Cephalosporins | 119.70 (107.10 – 243.80) | 105.90 (102.90 – 126.40) | 0.109 |
| | Benzylpenicillins | 264.80 (124.55 – 524.65) | 117.75 (103.17 – 262.07) | 0.461 |
| | Others | 144.10 (115.30 – 437.20) | 109.90 (101.20 – 132.50) | < 0.001* |
| Glucose | Cephalosporins | 6.59 (6.45 - 7.77) | 6.40 (6.00 - 6.76) | 0.045* |
| (mmol/L) | Benzylpenicillins | 8.47 (6.75 – 9.48) | 6.37 (5.88 – 7.86) | 0.109 |
| | Others | 7.80(6.77 - 9.10) | 6.78 (6.53 - 8.91) | 0.376 |
| GGT (U/L) | Cephalosporins | 120.00 (57.80 – 172.70) | 79.90 (49.10 – 157.60) | 0.064 |
| | Benzylpenicillins | 77.25 (50.67 – 123.05) | 76.70 (45.30 – 110.97) | 0.148 |
| | Others | 74.80 (47.60 – 125.60) | 74.80 (61.70 – 110.00) | 0.735 |
| Total Bilirubin (µmol/L) | Cephalosporins | 25.90 (10.80 – 56.60) | 12.40 (11.10 – 29.20) | 0.009* |
| | Benzylpenicillins | 108.66 (44.82 – 261.20) | 43.35 (31.35 – 176.55) | 0.612 |
| | Others | 20.50 (14.70 – 159.30) | 20.10 (12.70 – 38.80) | 0.080 |
| Direct bilirubin (µmol/L) | Cephalosporins | 14.40 (5.68 – 37.10) | 7.80 (5.40 – 19.40) | 0.015* |
| | Benzylpenicillins | 72.81 (31.20 – 170.40) | 24.30 (17.12 – 99.60) | 0.461 |
| | Others | 11.10 (6.90 – 99.20) | 9.80 (6.90 – 20.50) | 0.048* |
| Total protein (g/L) | Cephalosporins | 58.53 (54.70 – 63.30) | 60.50 (58.60 – 62.30) | 0.469 |
| | Benzylpenicillins | 59.75 (56.23 – 63.06) | 59.53 (54.25 – 61.73) | 0.641 |
| | Others | 62.30 (59.60 – 63.20) | 61.80 (58.80 – 63.00) | 0.244 |
| Urea (mmol/L) | Cephalosporins | 9.63 (8.22 – 20.39) | 7.35 (6.52 – 8.18) | 0.013* |
| | Benzylpenicillins | 20.52 (8.12 – 30.87) | 9.45 (7.56 – 18.40) | 0.945 |
| | Others | 17.45 (8.72 – 23.02) | 7.92 (6.65 – 8.63) | 0.010* |

- Figure 1. Average annual rate of confirmed leptospirosis cases per 100,000 population, European
- 300 Union/European Economic Area, 2010–2021. Adapted from ECDC [25]. The average number of
- leptospirosis cases in Ukraine is one of the highest in Europe, amounting to 0.73 per 100,000 people
- for the period 2010-2021. For comparison, in neighboring countries, the rate is 0.1 in Poland, 0.15 in
- 303 Slovakia, and 0.34 in Romania.
- Figure 2. Facet box plots of laboratory findings on admission and discharge in patients who took
- 305 dexamethasone
- 306 Statistically significant changes were observed in multiple parameters including LYM, MID, GRA,
- 307 RBC, MCV, PLT, AST, Direct bilirubin, and Urea levels.
- Figure 3. Box plots illustrating the Effect of steroids and antibiotics on Length of Stay (LoS).
- No significant changes were observed in patients receiving either steroids or antibiotics
- Figure 4. Direct bilirubin levels on admission as a potential predictor of lethality in leptospirosis.
- A. Box plot illustrating direct bilirubin levels on admission in surviving and non-surviving patients.
- B. ROC curve depicting the relationship between the probability of outcome and direct bilirubin.
- 313 C. Analysis of sensitivity and specificity of outcome based on direct bilirubin levels.




Figure 1




Figure 4



Figure 2




Figure 3